Pharmaceuticals Hong Kong

Hong Kong ADHD Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Hong Kong ADHD Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Type, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Hong Kong · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $31.7 Mn Placeholder estimate
Estimate 2025 $33.7 Mn 0.2% of the global market
Projected 2034 $60.0 Mn 77.8% Adds $26.2 Mn over 9 forecast years
CAGR 2025–2034 6.6% Faster than 19% of 180 Pharmaceuticals markets here
Key players 5
  • Hong Kong is 0.17% of the global market.
  • In APAC, the largest is China at $1.47 Bn.
  • Fastest growing: India at 8.6% a year.
  • Hong Kong ranks 7th of 10 by size in APAC.

Market size projection

Hong Kong

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$26.2 Mn total, 2026–2034

Year-by-year market size, 2024–2034
ADHD Drugs Market market size by year, Hong Kong
YearMarket sizeChange that yearSince 2025
2024 (estimate) $31.7 Mn — —
2025 (base) $33.7 Mn +$2.1 Mn —
2026 (forecast) $36.0 Mn +$2.2 Mn +6.6%
2027 (forecast) $38.4 Mn +$2.4 Mn +13.6%
2028 (forecast) $40.9 Mn +$2.5 Mn +21.1%
2029 (forecast) $43.6 Mn +$2.7 Mn +29.1%
2030 (forecast) $46.5 Mn +$2.9 Mn +37.7%
2031 (forecast) $49.5 Mn +$3.1 Mn +46.7%
2032 (forecast) $52.8 Mn +$3.3 Mn +56.4%
2033 (forecast) $56.3 Mn +$3.5 Mn +66.7%
2034 (forecast) $60.0 Mn +$3.7 Mn +77.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Hong Kong ADHD Drugs Market Analysis at a glance
Market size, 2025$33.7 Mn placeholder estimate
Forecast, 2034$60.0 Mn placeholder estimate
Growth (CAGR), 2025–20346.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledAttention Deficit Hyperactivity Disorder (ADHD) Drugs
SegmentsDrug type, age and end user (see all)
Key playersTakeda Pharmaceutical Company Ltd, Johnson & Johnson, Novartis AG, Supernus Pharmaceuticals, Teva Pharmaceutical (see all)
Regulator in Hong KongDrug OfficeSource: Drug Office, Department of Health. Checked 14 Nov 2026.
Active clinical trials7 in Hong KongSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Hong Kong ADHD Drugs Market Analysis Executive Summary

ADHD drugs treat attention deficit hyperactivity disorder in children and adults with stimulant and non-stimulant medicines.

Key segments of the ADHD Drugs market include drug type (Stimulants and Non-Stimulants) and age (Children, Adolescents and Adults).

Bar chart: Hong Kong ADHD Drugs market size, 2024–2034, placeholder estimates. $31.7 Mn in 2024, $33.7 Mn in 2025 and $60.0 Mn in 2034, 6.6% CAGR.
Hong Kong ADHD Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Hong Kong ADHD Drugs Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the ADHD Drugs market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the ADHD Drugs market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the ADHD Drugs market.

Competitive Landscape for ADHD Drugs Market in Hong Kong

The ADHD Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for ADHD Drugs Market in Hong Kong

ADHD Drugs in Hong Kong: rules, payment and research

Pharmaceutical products must be registered with the Pharmacy and Poisons Board before sale, through the Drug Office of the Department of Health.⁠[1] Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government.⁠[2] ClinicalTrials.gov lists 7 studies on ADHD Drugs that are recruiting, active or about to start in Hong Kong.⁠[3]

[1] Drug Office, Department of Health. Checked 14 Nov 2026.

[2] Hospital Authority. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for ADHD Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Hong Kong.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in ADHD Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

ADHD Drugs in context

Hong Kong compared

  • People aged 65 and over: 23.7% of people (2025). World: 10.4% of people (2025). 2nd highest of the 16 countries we cover in APAC.[1]

[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the ADHD Drugs market in Hong Kong?
Placeholder estimate: about $33.7 Mn in 2025, rising to about $60.0 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the ADHD Drugs market in Hong Kong growing?
Placeholder estimate: about 6.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the ADHD Drugs market report cover?
The report splits the market by drug type (Stimulants, Non-Stimulants), age (Children, Adolescents, Adults) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the ADHD Drugs market?
Key players include Takeda Pharmaceutical Company Ltd, Johnson & Johnson, Novartis AG, Supernus Pharmaceuticals and Teva Pharmaceutical.
What is driving the ADHD Drugs market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the ADHD Drugs market. Governments and employers are investing more in mental health care.
Who regulates ADHD Drugs in Hong Kong?
Pharmaceutical products must be registered with the Pharmacy and Poisons Board before sale, through the Drug Office of the Department of Health. Source: Drug Office, Department of Health. Checked 14 Nov 2026.
How is healthcare paid for in Hong Kong?
Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government. Source: Hospital Authority. Checked 14 Nov 2026.
How many clinical trials on ADHD Drugs are running in Hong Kong?
7 studies are recruiting, active or about to start in Hong Kong, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 12 Nov 2026.
How much research is published on ADHD Drugs?
PubMed lists 40 papers on ADHD Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Hong Kong

See all

Related on mental health

See the topic